Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology
about
Glioblastoma multiforme therapy and mechanisms of resistance.RNAi therapeutics for brain cancer: current advancements in RNAi delivery strategies.6-hydroxydopamine-induced Parkinson's disease-like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis.
P2860
Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Optimizing glioblastoma temozo ...... sed anti-MGMT shRNA technology
@en
Optimizing glioblastoma temozo ...... ed anti-MGMT shRNA technology.
@nl
type
label
Optimizing glioblastoma temozo ...... sed anti-MGMT shRNA technology
@en
Optimizing glioblastoma temozo ...... ed anti-MGMT shRNA technology.
@nl
prefLabel
Optimizing glioblastoma temozo ...... sed anti-MGMT shRNA technology
@en
Optimizing glioblastoma temozo ...... ed anti-MGMT shRNA technology.
@nl
P2093
P2860
P356
P1433
P1476
Optimizing glioblastoma temozo ...... sed anti-MGMT shRNA technology
@en
P2093
Andreas H Jacobs
Cornel Fraefel
Michael T Kuhlmann
Parisa Monfared
Sonja Schelhaas
P2860
P304
P356
10.1038/MT.2012.278
P577
2013-01-15T00:00:00Z